Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation

Status: Completed
Location: See all (26) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

To obtain data for the Rhythmia™ Mapping System in conjunction with Boston Scientific Open-Irrigated (OI) Catheters for ablation of Paroxysmal Atrial Fibrillation (PAF) according to current international and local guidelines. Primary objective: To assess acute and long-term outcomes for the Rhythmia Mapping System in conjunction with Boston Scientific Open-Irrigated Ablation Catheters to treat de novo Paroxysmal Atrial Fibrillation. De Novo PAF is defined as subjects undergoing first ablation procedure for PAF with no prior left atrial ablation (RF, Cryo, Surgical).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:

• History of recurrent symptomatic Paroxysmal Atrial Fibrillation, defined as AFib that terminates spontaneously or with intervention within seven days of onset. Minimum documentation includes a physician's note indicating recurrent self-terminating Atrial Fibrillation AND one electrocardiographically documented AF episode within 6 months prior to enrollment.

• Subjects who are eligible for an ablation procedure for Paroxysmal Atrial Fibrillation with the Rhythmia Mapping system according to current international and local guidelines

• Subjects who are eligible for an ablation procedure for Paroxysmal Atrial Fibrillation with a Boston Scientific Open-Irrigated Ablation Catheter according to current international and local guidelines

• Subjects who are willing and capable of providing informed consent

• Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center

• Subjects whose age is 20 years or above, or who are of legal age to give informed consent specific to state and national law.

Locations
United States
Alabama
University of Alabama at Birmingham
Birmingham
California
Torrance Memorial Medical Center
Torrance
Florida
Broward General Medical Center
Miami
AdventHealth Orlando
Orlando
Iowa
University of Iowa Hospitals and Clinics
Iowa City
Idaho
St. Lukes Idaho Cardiology Associates
Boise
Illinois
University of Chicago Hospital
Chicago
St. John's Hospital
Springfield
Nebraska
Nebraska Heart Institute
Lincoln
New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon
Catholic Medical Center
Manchester
New York
Kaleida Health
Buffalo
Ohio
Bethesda North Hospital
Cincinnati
Cleveland Clinic Foundation
Cleveland
Pennsylvania
Lehigh Valley Hospital
Allentown
Texas
HeartPlace Mid-Cities EP
Bedford
Orion Medical
Pasadena
Christus Trinity Mother Frances Health System
Tyler
Other Locations
Germany
Juedisches Krankenhaus Berlin
Berlin-mitte
Staedtisches Klinikum Karlsruhe
Karlsruhe
Japan
Kokura Memorial Hospital
Fukuoka-ken
Yokosuka Kyosai Hospital
Kanagawa Prefecture
Monaco
Centre Hospitalier Princesse Grace
Monaco
Republic of Korea
Keimyung University Dongsan Medical Center
Daegu
Korea University Medical Center
Seoul
United Kingdom
Papworth Hospital
Cambridge
Time Frame
Start Date: 2019-03-04
Completion Date: 2024-05-03
Participants
Target number of participants: 415
Related Therapeutic Areas
Sponsors
Leads: Boston Scientific Corporation

This content was sourced from clinicaltrials.gov